Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 1998

View Archived Issues

Inex R&D pipeline update

Cellegy and 3M combine technologies

CoCensys initiates phase II migraine study with ganaxolone tablets

Orphan drug status granted to Endorex's ImmTher for Ewing's sarcoma

SciClone's lead cystic fibrosis drug found safe in phase I

Elan completes acquisition of Carnrick

Neuprex receives orphan drug designation for treatment of severe meningococcal disease

rAd-p53 in gene therapy of cancers with p53 mutation; overview of gene therapies in development

Schering-Plough acquires Canadian rights to Ribi's melanoma theraccine

VIMRx updates stockholders at annual meeting

Ventana Genetics reports novel method for identification of drug target sites

Melphalan derivative pinpointed for further study

Biovail granted license to Celgene's ADHD treatment

New class of FPTase inhibitors discovered at Merck & Co.

Astra prepares another series of immunomodulatory peptides

Tricyclic antitumor compounds developed at Schering-Plough

Modulators of drug/multidrug resistance from Lilly

RPR acquires worldwide rights to Novartis anticoagulant

Phase II trial with HGP-30W HIV vaccine begins in The Netherlands

Elan/Neurex merger nears completion

Antisense therapy for CMV retinitis receives priority review status from FDA

Roche reviews HIV product pipeline in time for AIDS conference

Amur's AM-454 blocks progression of type II diabetes in preclinical studies

Preclinical studies with doranidazole summarized

Two-year landmark study demonstrates importance of initiating triple therapy simultaneously

Pyrazoloacridine evaluated in patients with pancreatic and hepatobiliary cancer

Various schedules and doses of DMDC explored in phase I

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...